This Week in Psychedelics

Scientists use AI to map psychedelic experiences in the brain. And Awakn's flagship London ketamine clinic receives regulatory approval.

March 18, 2022

This Week...

Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) received regulatory approval for its flagship ketamine clinic in London, which means it can now begin treating patients.  Click here for all the details:

On Monday, a Connecticut legislative committee discussed a bill that would set the state up to provide certain patients with access to psychedelic-assisted treatment with MDMA and psilocybin. Here’s more:

Scientists recently discovered that with artificial intelligence, they were able to map people’s subjective experiences while using psychedelics to specific regions of the brain, down to the molecular level. Amazing!  Check it out:

Did You Know?

Did you know that the CIA admitted to secretly dosing one of its employees with LSD, leading to his suicide… but that it was probably a cover story for something else?

When the MK-ULTRA program was uncovered in 1975, the apparent suicide of CIA employee Frank Olson in 1953 was blamed on his being given LSD nine days earlier. In Errol Morris’s documentary series Wormwood, however, it is speculated that Olson was in fact assassinated by his CIA superiors.  Here’s a peek: